What is Euphorine GNR©?

Good question! Euphorine is a revolutionary new solution produced by PROJECT ZENITH©, currently undergoing various trial stages. Euphorine is a fourth generation multi-phase mood stabilizer and alkaloid tricyclic. Traditional psychiatric drugs - in particular Monoamine Oxidase Inhibitors (MAOIs) - focus on inhibiting the activity of monoamine oxidase, thus preventing the breakdown of monoamine neurotransmitters and thereby increasing their availability, thus “alleviating” depressive symptoms.

The problem with traditional psychiatrics and psychiatric methods, which Euphorine seeks to dispel, is the singularity and exclusivity of the breakdown/neuro-emission process. For example, Isocarboxazid (Marplan©), a selective hydrazine-derived monoamine oxidase inhibitor, works by targeting ONLY such neuroreceptors as serotonin, epinephrine, and norepinephrine. Euphorine revolutionizes the neuro-emission process by selectively acting with ONLY those neurotransmitters in which there is an active monoamine deficiency.

It is with its unique monoamine selectivity that Euphorine derives its great implemental power - by acting selectively, Euphorine can be safely and effectively utilized in the treatment of depressive, somatic, disassociative, and virtually ALL mental disorders. Graduated dosage of Euphorine GNR© has been shown to stabilize neuroactivity in virtually ALL subjects, and alleviate virtually ALL mental disorders.

Canadian Residents may secure Euphorine GNR and other pharmaceuticals available at a fraction of the regular cost by calling: 1-866-375-2929
FDA's general position: The FDA, due to the current state of their regulations, has taken the position that virtually all shipments of prescription drugs imported from a Canadian pharmacy by a U.S. consumer will violate the law.

This is not an offering to any prospect located in, or for any location in, California, Hawaii, Illinois, Indiana, Maryland, Michigan, Minnesota, North Dakota, Rhode Island, South Dakota, Virginia, Washington, or Wisconsin. An offering can only be made in these states by providing you with a prospectus filed first with the relevant state administrator (in North Dakota, the Department of Law of the State of North Dakota). Any such filing does not constitute approval by the state administrator.